DBV Technologies S.A.
NASDAQ · us_market
No AI insight generated yet for this ticker.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | -0.09 | — | — |
| 2026-04-30 | -0.12 | -0.09 | +22.51% |
| 2026-03-26 | -0.19 | -0.20 | -5.73% |
| 2025-10-28 | -0.29 | -0.21 | +29.43% |
| 2025-07-29 | -0.16 | -0.27 | -71.61% |
| 2025-04-30 | -0.22 | -0.23 | -3.23% |
| 2025-03-24 | -0.21 | -0.21 | -1.26% |
| 2024-11-06 | -1.64 | -1.49 | +9.23% |
| 2024-07-30 | -2.65 | -1.57 | +40.62% |
| 2024-05-07 | -2.06 | -5.20 | -152.80% |
| 2024-03-07 | -2.43 | -2.01 | +17.33% |
| 2023-10-31 | -2.63 | -1.61 | +38.82% |
| 2023-07-31 | -2.27 | -2.36 | -3.93% |
| 2023-05-04 | -2.36 | -2.00 | +15.28% |
| 2023-03-02 | -1.71 | -8.49 | -395.35% |
| 2022-11-03 | -3.15 | -3.69 | -17.10% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| DBVT | -3.88% | -12.67% | -0.37% | +128.74% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.84% | -8.03% | +3.08% | +116.05% |